Servi­er’s vo­rasi­denib stalls pro­gres­sion of brain can­cer by 61% in piv­otal PhI­II IN­DI­GO study: #AS­CO23

An ex­per­i­men­tal pill from Servi­er Phar­ma­ceu­ti­cals showed po­ten­tial­ly prac­tice-chang­ing re­sults in a nar­row group of brain can­cer pa­tients, cut­ting the risk of their can­cers pro­gress­ing by 61%, ac­cord­ing to a late-stage clin­i­cal tri­al.

The drug, vo­rasi­denib, is a pre­ci­sion med­i­cine that on­ly works in cer­tain peo­ple whose can­cer car­ries mu­ta­tions in one of two genes called IDH1/2. Doc­tors hope that the ther­a­py will de­lay the need for chemother­a­py or ra­di­a­tion, which are of­ten used to com­bat re­laps­es in pa­tients who’ve pre­vi­ous­ly un­der­gone surgery to re­move brain tu­mors.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.